Circulatory System Diseases
The circulatory system plays a vital role in maintaining the overall health and functionality of our bodies. Our company, specializes in the development of drugs and therapies for rare circulatory system diseases, aiming to accelerate the development of rare disease therapies for global pharmaceutical companies.
Overview of Circulatory System Diseases
Circulatory system diseases encompass a wide range of conditions that affect the proper functioning of the heart, blood vessels, or blood itself. Circulatory system diseases can have various causes, including genetic predisposition, lifestyle factors, and underlying health conditions. Circulatory system diseases include cardiovascular diseases and vascular diseases.
- Cardiovascular Diseases
Cardiovascular diseases encompass a range of conditions that primarily affect the heart and blood vessels. Each of these conditions necessitates tailored therapy strategies to address the root causes and effectively manage symptoms.
- Vascular Diseases
Vascular diseases predominantly impact the integrity and functionality of the blood vessels, impairing their normal structure and function. These diseases can affect various vessels, including arteries, veins, and lymphatic vessels.
Fig.1 Showing novel targets and drugs for regulation of renin-angiotensin and aldosterone system in cardiovascular diseases. (Afzal, M., 2021)Pathogenesis of Circulatory System Diseases
Some of the key factors that contribute to the development of circulatory system diseases include:
- Genetic Factors: Inherited genetic abnormalities can predispose individuals to circulatory system diseases, such as familial hypercholesterolemia or certain types of arrhythmias.
- Inflammatory Conditions: Chronic inflammation, such as that seen in rheumatoid arthritis or lupus, can contribute to the development of circulatory system diseases.
- Diabetes: Uncontrolled diabetes can damage blood vessels and nerves, increasing the risk of heart disease, stroke, and peripheral artery disease.
- Heart Failure: Heart failure is a chronic condition where the heart is unable to pump blood effectively, leading to fatigue, shortness of breath, and fluid retention.
Therapy Development for Circulatory System Diseases
Small Molecule Drugs
Small molecule drugs have brought certain help to the development of therapy for circulatory system diseases. They may include blood thinners to prevent clotting, beta-blockers to control blood pressure, statins to lower cholesterol levels, and anti-arrhythmic drugs to regulate heart rhythm.
Targeted Therapies
The development of targeted therapies targeting specific molecular targets for circulatory diseases has broad application prospects, such as targeting coagulation factor VIII or coagulation factor IX to treat hemophilia, or treating thalassemia syndromes (TS) through stem cell transplantation.
Our Services
At our company, we have a dedicated team of scientists and researchers who work tirelessly to develop diagnostics and innovative therapies for circulatory system diseases. Our focus is on identifying novel drug targets, conducting preclinical studies, and advancing promising therapies to further study.
Rare Types of Circulatory System Diseases
| A-B | |
| Acquired Hemophilia A (AHA) | Acute Radiation Syndrome (ARS) |
| Alagille Syndrome (ALGS-1) | Angina Pectoris |
| Antiphospholipid Syndrome (APS) | Aplastic Anemia (AA) |
| Atypical Hemolytic Uremic Syndrome (aHUS) | Beta-Thalassemia (BT) |
| C-G | |
| Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | Congenital Thrombotic Thrombocytopenic Purpura (cTTP) |
| Cryopyrin-Associated Periodic Syndrome (CAPS) | Diamond-Blackfan Anemia (BDA) |
| Erythromelalgia | Erythropoietic Protoporphyria (EPP) |
| Galactosemia (GALAC1) | Glycogen Storage Disease II (GSD2) |
| H-M | |
| Heart Failure | Hemophilia A (HA) |
| Hemophilia B (HB) | Immunoglobulin Light Chain Amyloidosis |
| Leukocyte Adhesion Deficiency, Type I (LAD-1) | Myelodysplastic Syndromes (MDS) |
| Myelofibrosis (MF) | |
| P-S | |
| Paroxysmal Nocturnal Hemoglobinuria (PNH) | Porphyria |
| Polycythemia Vera (PV) | Porphyria Cutanea Tarda (FPCT) |
| Pre-Eclampsia | Purpura Fulminans (PF) |
| Pulmonary Hypertension (IPAH) | Sickle Cell Disease (SKCA) |
| T-W | |
| Thalassemia Syndromes (TS) | Thrombocythemia (THCYT) |
| Thromboangiitis Obliterans (TAO) | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) |
| Von Willebrand Disease (VWD) | Whim Syndrome (WHIM) |
| Warm Antibody Hemolytic Anemia (wAIHA) | |
Therapy Development Platforms
In addition, we offer animal model development services that encompass the creation and characterization of disease-specific models. These models enable us to study disease progression, test the efficacy and safety of potential therapies, and gain valuable insights into the biology of circulatory system diseases.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Afzal, M. "Recent updates on novel therapeutic targets of cardiovascular diseases." Mol Cell Biochem 476, 145–155 (2021).
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
